IRADIMED CORPORATION
IRMDHealthcareNASDAQMedical Devices · Last scanned Jul 17, 2026
Scan Results
Daily timeframeIRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring. At a $1.25B market cap, IRADIMED CORPORATION ranks as a small-cap company within healthcare. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device.
Market Cap
$1.25B
Beta
0.91
P/E (TTM)
53.43
P/E (Fwd)
41.52
EPS (TTM)
$1.83
EPS (Fwd)
$2.35
ROE
25.0%
ROA
16.2%
Cash
$56.4M
Total Debt
$0
Free CF
$15.2M
52W Change
70.2%
Annual Financials
Cash vs Debt
IRADIMED CORPORATION reports $56.4M in cash and $0 in total debt. Annual free cash flow of $15.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 25.0% points to strong capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Return on assets of 16.2% further supports the picture of efficient asset utilization. Revenue has grown from $53.3M (2022) to $83.8M (2025), reflecting a 57% increase over the period.
The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing IRMD.